AnaptysBio, Inc. (ANAB) vs Ultragenyx Pharmaceutical Inc. (RARE)
- AnaptysBio, Inc. ANAB 46.61 −4.31%
- Ultragenyx Pharmaceutical Inc. RARE 14.54 −4.15%
AnaptysBio, Inc. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. AnaptysBio, Inc. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.5B and $1.5B). AnaptysBio, Inc. grew revenue faster over the last twelve months: 107.7% against 17.5%. AnaptysBio, Inc. has the higher net margin (−11.5% vs −81.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, AnaptysBio, Inc. leads on 12 and Ultragenyx Pharmaceutical Inc. on 3.
Valuation
Profitability
| Metric | ANAB | RARE | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 83.12% | 65.16% |
| Operating margin | 17.56% | (73.64%) | 0.00% |
| Net margin | (11.53%) | (81.73%) | 0.00% |
| Free cash flow margin | 1.90% | (68.90%) | 0.00% |
| Return on equity | (114.55%) | 838.86% | (56.36%) |
| Return on assets | (7.13%) | (45.60%) | (48.04%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack